> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Davis Returning to CDER as Deputy Director
- URL: https://www.fdaweb.com/davis-returning-to-cder-as-deputy-director/
- Published: 2025-06-24T12:00:00.000Z
- Updated: 2026-09-14T15:15:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159410

Usona Institute chief medical officer **Michael C. Davis** is returning to CDER as the Center’s deputy director after being gone two and a half years, according to several media reports. He left the agency 12/2022 after serving almost seven years as a clinical team leader in CDER’s Division of Psychiatry. Davis’s return comes as CDER acting director **Jacqueline Corrigan-Curay** announced 6/23 her decision to retire next month ([see earlier story](https://www.fdaweb.com/cder-acting-head-corrigan-curay-leaving-in-july/)).

Usona Institute is described as a medical research organization “dedicated to supporting and conducting basic, pre-clinical and clinical research to further the scientific understanding and therapeutic application of consciousness-expanding medicines.” Davis was currently working on developing psychedelic drugs for treating major depressive disorder, according to his LinkedIn bio.

Davis obtained his medical degree from Case Western Reserve University School of Medicine and he has a Ph.D degree in pharmacology from Case Western Reserve University.